Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries
Author:
Open Access
- 24 September 2015
- journal article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 2 (3) , 117-124
Abstract
This paper aims at investigating (i) differences and commonalities of drugs Price and Reimbursement (P&R) criteria between Italy and the other major EU countries and (ii) comparative advantages, pitfalls and possible reforms of the Italian model. In the main EU countries P&R is converging towards a contractual model where therapeutic added value and economic impact are playing a crucial role. However there are still important differences across countries in the way added value is measured, the comparators are chosen and the economic impact is integrated with clinical evidence. Compared to the other systems the main advantages of the Italian model are (i) the explicit adoption of a multiple criteria approach, which has allowed a higher flexibility in P&R negotiation, and (ii) that managed market entry contracts have been often used to manage uncertainty at market launch. However, the assessment process is not transparent, innovativeness and premium price have never been explicitly integrated and price negotiation is strongly influenced by a budget silos approach. The former two pitfalls can be faced in the short-term, whereas giving up spending caps on drugs would require a longer-term political consensus.Keywords
This publication has 8 references indexed in Scilit:
- Current process and future path for health economic assessment of pharmaceuticals in FranceJournal of Market Access & Health Policy, 2015
- A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus FrancePharmacoEconomics, 2014
- Multi-tier drugs assessment in a decentralised health care system. The Italian case-studyHealth Policy, 2013
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislationThe European Journal of Health Economics, 2013
- Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluationHealth Policy, 2013
- Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providersAnnals of Oncology, 2010
- Public funding of new cancer drugs: Is NICE getting nastier?European Journal of Cancer, 2009